Evolent reported $725 million of quarterly revenue and $34.3 million of adjusted EBITDA, up approximately 22% sequentially, while raising full-year adjusted EBITDA guidance to $130 million to $135 million and reiterating revenue guidance of $2.6 billion to $2.7 billion.
EVH · Evolent Health, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Evolent Health reported September 30, 2026 quarter revenue of 725,367 thousand dollars and adjusted EBITDA of 34,257 thousand dollars. It raised 2026 adjusted EBITDA guidance to $130.0 million to $135.0 million and reiterated $2.6 billion to $2.7 billion revenue guidance.
Evolent Health reported revenue of $725.4 million for the three months ended September 30, 2026, up 51.3%, compared to 2025. Nine-month revenue rose 33.2% to $1.9 billion, while operating losses widened in both periods.